Background: Generic medicines are pharmaceutically equivalent alternatives to brand drugs that are marketed after patent expiry at substantially lower cost, without any difference in quality, safety, dosage form, strength, or intended clinical effect. Despite regulatory assurances of bioequivalence, public uptake of generics continues to be shaped by knowledge gaps, brand loyalty, and misconceptions about inferior quality. Objective: This study was undertaken to assess the level of awareness, knowledge, and perception of the general public toward generic medicines and to identify the socio-demographic and informational factors associated with a favourable attitude toward their use.Materials and Methods: A cross-sectional, questionnaire-based descriptive study was conducted among adult members of the general public using a pre-validated, structured questionnaire covering socio-demographic details, awareness, perception, and sources of information. Data were summarised using descriptive statistics, and associations between demographic variables and awareness/perception scores were examined using the Chi-square test, with p < 0.05 considered statistically significant.Results: Of the respondents, a majority had heard the term “generic medicine”, but a considerably smaller proportion could correctly describe its meaning in relation to bioequivalence and regulatory approval. Cost saving was the most widely recognised advantage, whereas doubts about efficacy, safety, and manufacturing quality were the most common reasons for hesitancy. Awareness and favourable perception were significantly associated with higher educational attainment and prior experience of using a generic medicine, while pharmacists and physicians emerged as the most trusted sources of information.Conclusion: Although the public is broadly familiar with the term “generic medicine”, true understanding of bioequivalence and regulatory oversight remains limited, and residual mistrust continues to restrict wider acceptance. Targeted public education, active promotion by prescribers and pharmacists, and transparent quality communication from regulators could meaningfully improve acceptance and rational use of generic medicines